ERBB2 and metastatic neoplasm: With the successful application of HER2-targeted therapy (especially trastuzumab) in the context of metastatic tumors and new diagnoses, the risk and prognosis of CNS in HER2-positive subgroups of patients have changed significantly, resulting in improved control of systemic disease(von Minckwitz et al. 2019).